Emily M. Kugler

Emily M. Kugler

Auto-generated profile, based on publicly available information

Emily M. Kugler

Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ASAdam Sateriale
Adam Sateriale
JGJodi A. Gullicksrud
Jodi A. Gullicksrud
JEJulie B. Engiles
Julie B. Engiles
BMBriana I. McLeod
Briana I. McLeod
EKEmily M. Kugler
Emily M. Kugler
BSBoris Striepen
Boris Striepen
Significance: The intestinal immune system is able to control pathogens while tolerating and interpreting microbial cues from an abundant microbiome. The mechanisms of innate recognition are crucial to differentiating between pathogen and commensal in this tissue and to mounting an appropriate inflammatory response. Persistent inflammation can alter the cellular architecture and physiology of the gut and have lasting impact on the nutritional state of children who face frequent infection with certain enteric pathogens. We demonstrate that the widespread parasite Cryptosporidium acts as a potent trigger for an enterocyte-intrinsic inflammasome that depends on the NOD-like receptor pyrin domain-6 and results in the local release of the proinflammatory cytokine IL-18.

1 December 2021 in JCO Oncology Practice
Verified
Journal Article
Closed access
LSLova Sun
Lova Sun
SSSanjna Surya
Sanjna Surya
NGNoah G. Goodman
Noah G. Goodman
ALAnh N. Le
Anh N. Le
GKGregory Kelly
Gregory Kelly
ADAngela DeMichele
Angela DeMichele
PURPOSE Multiple studies have demonstrated the negative impact of cancer care delays during the COVID-19 pandemic, and transmission mitigation techniques are imperative for continued cancer care delivery. We aimed to gauge the effectiveness of these measures at the University of Pennsylvania. METHODS We conducted a longitudinal study of SARS-CoV-2 antibody seropositivity and seroconversion in patients presenting to infusion centers for cancer-directed therapy between May 21, 2020, and October 8, 2020. Participants completed questionnaires and had up to five serial blood collections. RESULTS Of 124 enrolled patients, only two (1.6%) had detectable SARS-CoV-2 antibodies on initial blood draw, and no initially seronegative patients developed newly detectable antibodies on subsequent blood draw(s), corresponding to a seroconversion rate of 0% (95% CI, 0.0 TO 4.1%) over 14.8 person-years of follow up, with a median of 13 health care visits per patient. CONCLUSION These results suggest that patients with cancer receiving in-person care at a facility with aggressive mitigation efforts have an extremely low likelihood of COVID-19 infection. (C) 2021 by American Society of Clinical Oncology